You just read:

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 11, 2019, 16:30 ET